Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Barratt, C. Jarrett, T. Blythe, K. Ourradi, G. Welsh, D. Bates, A. Millar (Bristol, United Kingdom). LSC 2013 abstract - Bioavailability of VEGF in idiopathic pulmonary fibrosis. Eur Respir J 2013; 42: Suppl. 57, 4881

Member's Comments

No comment yet.

Related content which might interest you: LSC 2010 Abstract: Overexpression of Ang-(1-7)-fusion protein in the lungs prevents pulmonary fibrosis and accompanying pulmonary hypertension Source: Annual Congress 2010 - Pre-clinical models of airways disease Year: 2010 Late-breaking abstract: Pathological analysis of acute exacerbation of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011 Late Breaking Abstract - Pharmacokinetics (PK) of nintedanib with add-on pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): results from INJOURNEY Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 LSC 2011 Abstract: Role of mast cells and chymase in idiopathic pulmonary fibrosis Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases Year: 2011 Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain. Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis Source: Eur Respir Rev 2012; 21: 147-151 Year: 2012 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Late Breaking Abstract - Safety of combined pirfenidone (PFD) and nintedanib (NIN) in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – Late-breaking findings in pulmonary diseases Year: 2017 Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early Spanish experience with the European Named patient program (NPP) Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Prognostic evaluation in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 LATE-BREAKING ABSTRACT: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014 Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Development of the interstitial lung disease multidiciplinary team meeting 2005-2013 Source: International Congress 2015 – Kaleidoscope of nursing research Year: 2015 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – IPF pathogenesis Year: 2015 Safety and efficacy of pirfenidone in patients with lung fibrosis and TERT mutation Source: International Congress 2016 – IPF pathogenesis Year: 2016